Grown Rogue Enters New York via PharmaCann Asset Deal with $15M Project Financing
GRUSF sits 63% above its 52-week low of $0.269.
Summary
Grown Rogue has closed initial transactions to enter New York through a planned acquisition of PharmaCann's New York license and assets, including a 24,000 sq ft indoor cultivation facility and four Verilife dispensaries. The deal is structured through a 51/49 JV with a capital partner providing $10M preferred equity and a $5M term loan commitment. Management expects $20M in annual cost savings and projects the New York operations to be cash flow positive within nine months, generating $600K monthly after-tax cash flow within 18 months. This is a transformational expansion into a major market, following strong Q2 results and raised guidance. Key risks include regulatory approval, execution of definitive agreements, and the six-to-nine month production ramp.
At the time of this announcement, GRUSF was trading at $0.44 on OTC in the Trade & Services sector. The 52-week trading range was $0.27 to $0.52. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.